CRISPR and Gene Editing in Pharmaceuticals Market By Application: Genetic Modification, Research, By End-Use: Research Institutions, Pharmaceutical Companies, By Region: North America, Europe, Asia Pacific, Segment Forecasts: 2024 - 2030
CRISPR and Gene Editing in Pharmaceuticals Market Trends
The CRISPR and gene editing in pharmaceuticals market was valued at USD 4.6 billion in 2024 and is projected to grow at a CAGR of 25.1% from 2025 to 2030. The adoption of CRISPR technology is transforming the pharmaceutical landscape by enabling precise genetic modifications.
Product Insights
Genetic modification applications accounted for the largest share in 2024, contributing 62.4% of total revenue, as researchers leverage CRISPR for gene editing and therapeutic development. Research applications are also gaining traction, driving advancements in genetic research.
End-Use Insights
Research institutions represented the largest end-users in 2024, holding a 66.9% market share, as they utilize CRISPR technology for innovative research applications. Pharmaceutical companies are increasingly adopting CRISPR technologies to enhance drug development processes.
Regional Insights
North America dominated the CRISPR and gene editing market with a 49.7% share in 2024, fueled by extensive research initiatives and a strong biotechnology ecosystem. The Asia Pacific region is anticipated to grow rapidly, with a CAGR of 27.5%, driven by increasing investments in gene editing technologies.
GET A FREE SAMPLE
This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.